COSMO Pharmaceuticals SA (0RGI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has a cash flow conversion efficiency ratio of -0.013x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (£-7.38 Million ≈ $-9.91 Million USD) by net assets (£573.73 Million ≈ $770.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 0RGI company net worth for the company's overall valuation and market capitalisation.
COSMO Pharmaceuticals SA - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how COSMO Pharmaceuticals SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
COSMO Pharmaceuticals SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSMO Pharmaceuticals SA ranked by their cash flow conversion efficiency. Explore cash flow quality index of COSMO Pharmaceuticals SA to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hagar hf
IC:HAGA
|
0.078x |
|
PROS Holdings Inc
NYSE:PRO
|
-0.149x |
|
Faraday Copper Corp.
TO:FDY
|
0.012x |
|
Alphamin Resources Corp.
JSE:APH
|
0.124x |
|
Zimplats Holdings Ltd
AU:ZIM
|
-0.001x |
|
Sinomach Automobile Co Ltd
SHG:600335
|
-0.072x |
|
Brighton-Best International Taiwan
TWO:8415
|
0.065x |
|
Xinlei Compressor Co. Ltd. A
SHE:301317
|
N/A |
Annual Cash Flow Conversion Efficiency for COSMO Pharmaceuticals SA (2004–2025)
The table below shows the annual cash flow conversion efficiency of COSMO Pharmaceuticals SA from 2004 to 2025. View COSMO Pharmaceuticals SA (0RGI) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | £488.80 Million ≈ $656.41 Million |
£-11.62 Million ≈ $-15.60 Million |
-0.024x | -107.39% |
| 2024-12-31 | £505.09 Million ≈ $678.29 Million |
£162.41 Million ≈ $218.10 Million |
0.322x | +310.30% |
| 2023-12-31 | £429.04 Million ≈ $576.16 Million |
£33.62 Million ≈ $45.15 Million |
0.078x | +10.49% |
| 2022-12-31 | £463.79 Million ≈ $622.83 Million |
£32.89 Million ≈ $44.17 Million |
0.071x | +188.34% |
| 2021-12-31 | £512.68 Million ≈ $688.48 Million |
£12.61 Million ≈ $16.94 Million |
0.025x | -24.20% |
| 2020-12-31 | £400.12 Million ≈ $537.33 Million |
£12.98 Million ≈ $17.44 Million |
0.032x | +167.80% |
| 2019-12-31 | £393.73 Million ≈ $528.75 Million |
£-18.85 Million ≈ $-25.31 Million |
-0.048x | -109.50% |
| 2018-12-31 | £444.85 Million ≈ $597.40 Million |
£-10.16 Million ≈ $-13.65 Million |
-0.023x | -13.93% |
| 2017-12-31 | £470.12 Million ≈ $631.32 Million |
£-9.43 Million ≈ $-12.66 Million |
-0.020x | -138.42% |
| 2016-12-31 | £415.56 Million ≈ $558.06 Million |
£21.69 Million ≈ $29.13 Million |
0.052x | +153.67% |
| 2015-12-31 | £403.65 Million ≈ $542.06 Million |
£-39.26 Million ≈ $-52.72 Million |
-0.097x | -122.29% |
| 2014-12-31 | £152.29 Million ≈ $204.51 Million |
£66.45 Million ≈ $89.23 Million |
0.436x | +1084.01% |
| 2013-12-31 | £220.16 Million ≈ $295.65 Million |
£8.11 Million ≈ $10.90 Million |
0.037x | -80.04% |
| 2012-12-31 | £150.41 Million ≈ $201.98 Million |
£27.76 Million ≈ $37.29 Million |
0.185x | +3.72% |
| 2011-12-31 | £63.43 Million ≈ $85.19 Million |
£11.29 Million ≈ $15.16 Million |
0.178x | +33.42% |
| 2010-12-31 | £58.37 Million ≈ $78.38 Million |
£7.79 Million ≈ $10.46 Million |
0.133x | +105.80% |
| 2009-12-31 | £59.80 Million ≈ $80.30 Million |
£3.88 Million ≈ $5.21 Million |
0.065x | +122.39% |
| 2008-12-31 | £43.24 Million ≈ $58.06 Million |
£-12.52 Million ≈ $-16.81 Million |
-0.290x | -303.62% |
| 2007-12-31 | £35.15 Million ≈ $47.20 Million |
£-2.52 Million ≈ $-3.39 Million |
-0.072x | -106.31% |
| 2006-12-31 | £5.34 Million ≈ $7.18 Million |
£6.08 Million ≈ $8.16 Million |
1.137x | -57.78% |
| 2005-12-31 | £631.00K ≈ $847.38K |
£1.70 Million ≈ $2.28 Million |
2.694x | +1008.37% |
| 2004-12-31 | £-880.00K ≈ $-1.18 Million |
£261.00K ≈ $350.50K |
-0.297x | -- |
About COSMO Pharmaceuticals SA
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant… Read more